Proposal and validation of a liver graft discard score for liver transplantation from deceased donors: a multicenter Italian study - Takeaways - MDSpire

Proposal and validation of a liver graft discard score for liver transplantation from deceased donors: a multicenter Italian study

  • By

  • Quirino Lai

  • Davide Ghinolfi

  • Alfonso W. Avolio

  • Tommaso M. Manzia

  • Gianluca Mennini

  • Fabio Melandro

  • Francesco Frongillo

  • Marco Pellicciaro

  • Zoe Larghi Laureiro

  • Rebecca Aglietti

  • Antonio Franco

  • Claudia Quaranta

  • Giuseppe Tisone

  • Salvatore Agnes

  • Massimo Rossi

  • Paolo de Simone

  • March 11, 2022

  • 0 min

Share

  • 1

    This study developed a liver graft discard score to predict the risk of liver-related graft discard from deceased donors after brain death.

  • 2

    A total of 4,207 deceased donor liver grafts were analyzed, with 2,642 (62.8%) deemed eligible for transplantation and 1,565 (37.2%) discarded.

  • 3

    Liver-related issues accounted for 1,254 graft discards (29.8%), with poor histology being the most common reason at 15.7%.

  • 4

    The study utilized a training set of 3,156 candidates and a validation set of 1,051 candidates to assess the score's predictive accuracy.

  • 5

    Statistical analysis included competing-risk models and c-statistic evaluations, demonstrating the score's effectiveness compared to existing indices.

Original Source(s)

Proposal and validation of a liver graft discard score for liver transplantation from deceased donors: a multicenter Italian study

  • by Quirino Lai, Davide Ghinolfi, Alfonso W. Avolio, Tommaso M. Manzia, Gianluca Mennini, Fabio Melandro, Francesco Frongillo, Marco Pellicciaro, Zoe Larghi Laureiro, Rebecca Aglietti, Antonio Franco, Claudia Quaranta, Giuseppe Tisone, Salvatore Agnes, Massimo Rossi, Paolo de Simone

  • March 11, 2022

Related Content

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Mortality following elective and emergency colectomy in patients with cirrhosis: a population-based cohort study from England

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.